Skip to Content
  • Previous Rank
    254
  • Revenues ($M)
    $13,003.00
  • Revenue Percent Change
    15.8%
  • Profits ($M)
    $2,940.00
  • Profits Percent Change
    47.1%
  • Assets ($M)
    $30,141.00
  • Employees
    7,467
  • Market Value — as of March 29, 2018 ($M)
    $67,101.60

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
Mark J. Alles
CEO Title
Chairman & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Summit, N.J.
Websitehttp://www.celgene.com
Years on Fortune 500 List7
Employees7,467

Celgene Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$13,003.0015.8%
Profits ($M)$2,940.0047.1%
Assets ($M)$30,141.00-
Total Stockholder Equity ($M)$6,921.00-
Market Value — as of March 29, 2018 ($M)$67,101.60-

Profit Ratios

Profit as % of Revenues22.6%
Profits as % of Assets9.8%
Profits as % of Stockholder Equity42.5%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)3.64
EPS % Change (from 2016)46.2%
EPS % Change (5 year annual rate)17.1%
EPS % Change (10 year annual rate)29.7%

Total Return

Total Return to Investors (2017)-9.8%
Total Return to Investors (5 year, annualized)21.6%
Total Return to Investors (10 year, annualized)16.3%